» Articles » PMID: 25951495

Selective Depletion of Tumor Neovasculature by Microbubble Destruction with Appropriate Ultrasound Pressure

Overview
Journal Int J Cancer
Specialty Oncology
Date 2015 May 8
PMID 25951495
Citations 22
Authors
Affiliations
Soon will be listed here.
Abstract

Low-intensity ultrasound-microbubble (LIUS-MB) treatment is a promising antivascular therapy for tumors. We sought to determine whether LIUS-MB treatment with an appropriate ultrasound pressure could achieve substantial and persistent cessation of tumor perfusion without having significant effects on normal tissue. Further, we investigated the mechanisms underlying this treatment. Murine S-180 sarcomas, thigh muscles, and skin tissue from 60 tumor-bearing mice were subjected to sham therapy, an ultrasound application combined with microbubbles in four different ultrasound pressures (0.5, 1.5, 3.0, 5.0 MPa), or ultrasound at 5.0 MPa alone. Subsequently, contrast-enhanced ultrasonic imaging and histological studies were performed. Tumor microvessels, tumor cell necrosis, apoptosis, tumor growth, and survival were evaluated in 85 mice after treatment with the selected ultrasound pressure. We found that twenty-four hours after LIUS-MB treatment at 3.0 MPa, blood perfusion and microvessel density of the tumor had substantially decreased by 84 ± 8% and 84%, respectively (p < 0.01). Similar reductions were not observed in the muscle or skin. Additionally, an extreme reduction in the number of immature vessels was observed in the tumor (reduced by 90%, p < 0.01), while the decrease in mature vessels was not significant. Further, LIUS-MB treatment at 3.0 MPa promoted tumor cell necrosis and apoptosis, delayed tumor growth, and increased the survival rate of tumor-bearing mice (p < 0.01). These findings indicate that LIUS-MB treatment with an appropriate ultrasound pressure could selectively and persistently reduce tumor perfusion by depleting the neovasculature. Therefore, LIUS-MB treatment offers great promise for clinical applications in antivascular therapy for solid tumors.

Citing Articles

Downregulation of carbonic anhydrase IX expression in mouse xenograft nasopharyngeal carcinoma model via doxorubicin nanobubble combined with ultrasound.

Li R, Lu L, Huang Z, Gao Y Open Med (Wars). 2024; 19(1):20240910.

PMID: 38463523 PMC: 10921437. DOI: 10.1515/med-2024-0910.


Ultrasound-mediated drug-free theranostics for treatment of prostate cancer.

Perera R, Berg F, Abenojar E, Nittayacharn P, Kim Y, Wang X Bioact Mater. 2024; 35:45-55.

PMID: 38304914 PMC: 10831121. DOI: 10.1016/j.bioactmat.2023.12.012.


Efficient ultrasound-mediated drug delivery to orthotopic liver tumors - Direct comparison of doxorubicin-loaded nanobubbles and microbubbles.

Nittayacharn P, Abenojar E, Cooley M, Berg F, Counil C, Sojahrood A J Control Release. 2024; 367:135-147.

PMID: 38237687 PMC: 11700473. DOI: 10.1016/j.jconrel.2024.01.028.


Synchronous Intravital Imaging and Cavitation Monitoring of Antivascular Focused Ultrasound in Tumor Microvasculature Using Monodisperse Low Boiling Point Nanodroplets.

Pellow C, Sojahrood A, Zhao X, Kolios M, Exner A, Goertz D ACS Nano. 2023; 18(1):410-427.

PMID: 38147452 PMC: 10786165. DOI: 10.1021/acsnano.3c07711.


Efficient ultrasound-mediated drug delivery to orthotopic liver tumors - Direct comparison of doxorubicin-loaded nanobubbles and microbubbles.

Nittayacharn P, Abenojar E, Cooley M, Berg F, Counil C, Sojahrood A bioRxiv. 2023; .

PMID: 37732235 PMC: 10508722. DOI: 10.1101/2023.09.01.555196.


References
1.
Gilbert M, Dignam J, Armstrong T, Wefel J, Blumenthal D, Vogelbaum M . A randomized trial of bevacizumab for newly diagnosed glioblastoma. N Engl J Med. 2014; 370(8):699-708. PMC: 4201043. DOI: 10.1056/NEJMoa1308573. View

2.
Wood A, Ansaloni S, Ziemer L, Lee W, Feldman M, Sehgal C . The antivascular action of physiotherapy ultrasound on murine tumors. Ultrasound Med Biol. 2005; 31(10):1403-10. PMC: 2442571. DOI: 10.1016/j.ultrasmedbio.2005.06.008. View

3.
Wood A, Bunte R, Cohen J, Tsai J, Lee W, Sehgal C . The antivascular action of physiotherapy ultrasound on a murine tumor: role of a microbubble contrast agent. Ultrasound Med Biol. 2007; 33(12):1901-10. PMC: 2423191. DOI: 10.1016/j.ultrasmedbio.2007.06.013. View

4.
Skyba D, Price R, Linka A, Skalak T, Kaul S . Direct in vivo visualization of intravascular destruction of microbubbles by ultrasound and its local effects on tissue. Circulation. 1998; 98(4):290-3. DOI: 10.1161/01.cir.98.4.290. View

5.
Leite de Oliveira R, Deschoemaeker S, Henze A, Debackere K, Finisguerra V, Takeda Y . Gene-targeting of Phd2 improves tumor response to chemotherapy and prevents side-toxicity. Cancer Cell. 2012; 22(2):263-77. DOI: 10.1016/j.ccr.2012.06.028. View